ACCIÓ awards the Institute’s Innovation Department with the quality seal TECNIO and two VALUNI grants for technology transfer projects
"El Mundo" publishes an article about an IRB Barcelona research project funded by two patient associations, the international BabelFamily and Asogaf from Granada, that is devoted to finding a treatment for the neurodegenerative disease Friedreich's Ataxia.
Meritxell Teixidó and Macarena Sánchez, scientists behind the project, which also involves Ernest Giralt, explain that the "challenge is to transform it into a chronic disease; the dream would be to halt it or to slow down the degeneration".
Link to El Mundo
The newspaper "El Periódico" has reported on an IRB Barcelona research project on Friedreich’s ataxia disease, funded by the patient and family association, the Babel Family, and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF). The disease is caused by a defect in a gene, frataxin, which results in reduced levels of this protein in the body, particularly affecting the brain, spinal cord and muscles.
The project aims to develop an injectable frataxin treatment that can reach the brain, "like the injection of insulin for diabetics", explains Ernest Giralt,...
High impact in the international media of Ernest Giralt's latest work presented at the meeting of the American Chemical Society in San Francisco. Giralt, head of the Design, Synthesis and Structure of Peptides and Proteins Lab at IRB Barcelona, is working on transforming a protein from bee venom into a tool that helps treatments get inside the brain.
“We thought that because the venoms of some animals are able to attack the central nervous system, they should be able to go through the blood-brain barrier and possibly shuttle drugs across it," explains Giralt.
Link to ...
Radio 5 (RNE) interviews Ernest Giralt, head of the Design, Synthesis and Structure of Peptides and Proteins Lab at IRB Barcelona, and Macarena Sánchez, research associate in the same Lab, about IRB Barcelona’s research to tackle Friedreich’s ataxia. In the interview, Giralt explains that Friedreich’s ataxia is a hereditary degenerative disease that normally appears between the ages of 5 and 25, for which there is currently no cure.
IRB Barcelona’s project, supported by the patient and family association, the Babel Family, and the Asociación Granadina de la ataxia de Friedreich, aims to complete a step necessary to move towards a future frataxin replacement therapy for...
IRB Barcelona starts a project with the long-term goal to achieve an injectable frataxin treatment able to reach the brain.
Frataxin is the protein that is reduced in those affected by this rare and degenerative disease, which has no cure.
The patients’ associations Babel Family and ASOGAF in Granada provide the funding for the initial 18 months of this challenge.
Several media have echoed the research project on Friedreich’s Ataxia at IRB Barcelona, funded by the associations of patients and families called the Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF), for the initial 18 months.
The project aims to develop an injectable frataxin treatment that can reach the brain. Frataxin is the protein that is reduced in those affected by this rare and degenerative disease, which has no cure.
The Generalitat’s (Catalan Government) Universities and Research website has echoed on the research performed by scientists at IRB Barcelona and the UB, namely a shuttle produced from a peptide present in bee venom and capable of transporting molecules into the brain.
The research results arose from the Benjamí Oller's PhD thesis, done in Professor Ernest Giralt's Lab at IRB Barcelona and defended in 2015. In January 2016, he started his postdoctoral training in Cambridge, UK.
Link to Universities and...
Cristina Fuster (Girona, 1989) is the first IRB Barcelona student to participate in the academic exchange programme recently signed with the Graduate School of Pharmaceutical Sciences of the Tohoku University in North East Japan.
Compound IPR19, a drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.